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  Many variables of the QT interval have been used for the risk 
stratification of various cardiovascular diseases. The QT interval represents 
the repolarization phase of the ventricles and this phase is important for the 
process of EC coupling of the myocardium. Changes in electrophysiological 
balance in the repolarization phase have the potential for both 
antiarrhythmic and proarrhythmic effects. Initially, QT interval abnormality 
(that is, QT prolongation) was recognized in children with sudden death. 
Almost 60 years passed after the recognition of the first long QT syndrome 
cases, and the QT interval is still the most important clinical characteristic and 
predictor of prognosis in patients with long QT syndrome1. QT prolongation has also 
been applied for prediction of various cardiovascular diseases and prolonged QT 
interval has been linked to an increased risk of cardiovascular death2.  
The QT segment is not stable. Since the QT interval is influenced by previous 
RR interval or diastolic interval (interval between the end of T wave of the previous 
beat and the onset of R wave of the present beat), variability of the QT segment is 
strongly associated with variability of the previous RR intervals. Moreover, the QT 
interval also depends on a much longer history of the previous RR intervals 2-3 min 
before the present beats (QT hysteresis). Although some indices of QT variability have 
been proposed to reduce the influence of RR variance on the QT interval, detection of 
microvolt T-wave alternans (MTWA)3 is a most popular method to detect repolarization 
instability. MTWA can detect electrical instability as the presence of T-wave amplitude 
at a 0.5 cycle-per-beat periodicity and requires a stress test to increase the heart rate for 
induction of the MTWA. Although a few studies failed to show the predictive value of 
the MTWA4, 5, most of the studies and meta-analysis found the positive MTWA as a 
risk factor for sudden cardiac death in patients with heart failure6, 7. The QT variability 
index (QTVI) is an alternative method to detect beat-to-beat changes in the 
repolarization duration, adjusting the measurement for heart rate variance8. Usually 5 to 
10 minutes-ECG recording at rest is available to analyze the QTVI and it also can detect 
both alternate and non-alternate QT oscillations. The magnitude of alternate and 
non-alternate T wave oscillations increased immediately before the onset of ventricular 
tachyarrhythimia9 and the QTVI is a useful method to identify unstable repolarization 
variability that MTWA fails to detect. Previous studies showed patients with ischemic 
or non-ischemic dilated cardiomyopathy had increased QTVI compared to control 
subjects8, 10, 11. The value of QTVI depended on severity of New York Heart 
Association (NYHA) functional class and was a predictor of total mortality, sudden 
cardiac death, and occurrence of ventricular tachyarrhythmias. The QTVI did not 
correlate with heart rate variability, which usually is reduced in heart failure.  
In this issue of the Journal, Dobson et al12 reported that QTVI was associated 
with increased risk for total and cardiovascular mortality in patients with heart failure 
from the GISSI-HF trial. Since the QTVI had circadian variation that was the lowest in 
the midnight to early morning hours and increased throughout the day13, authors used 
data from the 24-hour Holter ECG recording and found QTVI at high heart rate did not 
have predictable value but the QTVI at low heart rate had significant results. The 
present and previous studies indicate that increased QTVI is associated with poor 
prognosis in patients with heart failure.  
One can ask why the increased variability of QT interval is not good for 
patients with heart failure. The answer is that abnormal QT interval variability 
represents the results of electrical remodeling in the failing heart. Reduced cardiac 
output in the failing heart promotes sympathetic neurohumoral activation and 
electrophysiological changes in the failing myocardium14 to increase cardiac output and 
maintain systemic perfusion, but these compensatory responses also have 
arrhythmogenic effects. Electrophysiological changes in the failing myocyte result in 
prolongation of the action potential duration to enhance intracellular Ca2+ handling and 
cardiac contractility. The outward K+ currents are downregulated15 in failing hearts by 
alteration of the channel kinetics or reduced expression of the channel proteins. 
Alterations in intracellular Ca2+ handling in the failing myocyte cause prolongation of 
the Ca2+ transient and intracellular Ca2+ overload. Increased Na+/Ca2+ exchanger activity 
attempts to reduce Ca2+ overload but it causes inward depolarizing current and promotes 
triggered activity through early and delayed afterdepolarizations14. Conduction 
disturbances occur from myocardial fibrosis or downregulation of connexin and can be 
a substrate for reentrant ventricular arrhythmias. Oscillation of the action potential is 
associated with the alternation of overloading in the Ca2+ transient cascade and 
initiation of afterdepolarizations, all enhanced by increased sympathetic nervous 
activity. Experimentally, transient activation of the sympathetic nerve increases QT 
variability and induces arrhythmias in the canine model of the pacing-induced heart 
failure16. 
If QT variability represents unstable repolarization, how can we stabilize QT 
variability? Because QTVI is associated with severity of NYHA functional class, 
treatment of heart failure could stabilize QT oscillations. Since adrenergic stimulation 
enhances the occurrence of QT variability, adequate beta-blocker therapy reduces the 
QTVI17. Although both metoprolol and carvedilol improved the QTVI in patients with 
heart failure, the effect of carvedilol on stabilization of the QTVI was superior than 
metoprolol17. Stabilization of QT variability can be one of the mechanisms of reduction 
of sudden death or ventricular tachyarrhythmia by beta-blocker in patients with heart 
failure. Although class III antiarrhythmic drugs seem not to influence on the QTVI at 
therapeutic doses18, QT variability increases under conditions of drug-induced long QT 
syndrome with torsades de pointes19.  
In this issue of the Journal from the GISSI-HF trial, Dobson et al12 did not 
mention therapeutic effects on the QTVI. The original GISSI-HF trial reported that ω-3 
polyunsaturated fatty acid (PUFA) from fish oil reduced cardiovascular mortality in 
patients with heart failure20 and a substudy supported the antiarrhythmic effects of the 
PUFA21. Antiarrhythmic effects of ω-3 PUFA are still controversial but PUFA can 
modulate electrophysiological properties of cardiac myocytes. Experimental studies 
showed that ω-3 PUFA reduces Ca2+ overload and aftertransients, and normalization of 
Ca2+ handling prevents occurrence of delayed afterdepolarizations and triggered activity 
in failing myocytes22, 23. Moreover ω-3 PUFA reduces L-type Ca2+ and Na+/Ca2+ 
exchanger currents, and enhances the slow component of the delayed rectifier K+ 
current. These electrophysiological effects of ω-3 PUFA may reduce repolarization 
oscillation and the QTVI. Future studies should explore the effects of fish oil on the 
QTVI in the patients with heart failure.
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